Selective vulnerability of myeloma survival kinases. (A-D) Effect on viability of siRNA directed against top-ranked myeloma survival kinases in (A) KMS11 and (B) JJN3 myeloma cells, and in (C) 293 embryonic kidney and (D) A549 lung carcinoma cells. Cells were transfected with 2 unique siRNAs per kinase in separate wells, using conditions optimized for each cell line each associated with > 90% transfection efficiency. Viability was assessed at 96 hours and is plotted in units of standard deviations from control siRNA. (E-F) Western blot analysis of kinase knockdown after siRNA targeting of (E) AURKA and (F) PKN1, confirming equivalent or greater transfection and protein knockdown in 293 and A549 cells, compared with KMS11 myeloma cells. Cells were transfected using the same conditions as panels A through D optimized for each line, and lysates were prepared at 48 hours; 10 μg of total protein was loaded per lane.